Madrigal Pharmaceuticals Inc
MDGLHealthcare|Biotechnology|USA
$536.70
-23.77 (-4.24%)
Tangible Book
$23.27
Clinical Trials (18)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05500222 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | NASH, Cirrhosis, Liver | P3 | Active | 845 | RCT, Double-blind | Resmetirom, Placebo |
| NCT03900429 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | NASH - Nonalcoholic Steatohepatitis | P3 | Active | 1,759 | RCT, Double-blind | MGL-3196, Placebo |
| NCT04951219 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Non-Alcoholic Fatty Liver Disease | P3 | Active | 810 | RCT, Double-blind | Resmetirom |
| NCT07335601 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | P2 | Recruiting | 120 | RCT, Double-blind | Resmetirom, Placebo |
| NCT07541469 Rezdiffra Pregnancy and Lactation Registry | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 10 | — | Rezdiffra | |
| NCT04197479 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients | Non-Alcoholic Fatty Liver Disease | P3 | Completed | 1,343 | RCT, Double-blind | Placebo, Resmetirom |
| NCT02912260 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Non-alcoholic Steatohepatitis | P2 | Completed | 125 | RCT, Double-blind | MGL-3196, Placebo |
| NCT03038022 Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | Heterozygous Familial Hypercholesterolemia | P2 | Completed | 116 | RCT, Double-blind | MGL-3196 (resmetirom), Placebo |
| NCT04643795 Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects | Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 87 | Open-label | MGL-3196 |
| NCT02542969 Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | Healthy | P1 | Completed | 25 | Open-label | Simvastatin, Rosuvastatin, MGL-3196 |
| NCT01519531 Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Drug Safety | P1 | Completed | 48 | RCT, Double-blind | Placebo, VIA-3196 |
| NCT04671056 Drug Interaction Study of MGL-3196 With Pioglitazone | Healthy | P1 | Completed | 16 | Open-label | MGL-3196, Pioglitazone 15mg |
| NCT03220165 Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 | Healthy | P1 | Completed | 8 | Open-label | MGL-3196 |
| NCT01367873 Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Drug Safety | P1 | Completed | 72 | RCT, Double-blind | Placebo, VIA-3196 |
| NCT03413124 Bioavailability Study of MGL-3196 Tablets Compared to Capsules | Healthy | P1 | Completed | 16 | RCT, Open-label | MGL-3196 Tablet, MGL-3196 Capsule |
| NCT06397872 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function | Renal Impairment | P1 | Completed | 28 | Open-label | 100 mg Resmetirom Tablet |
| NCT04671069 Drug Interaction Study of MGL-3196 With Clopidogrel | Healthy | P1 | Completed | 20 | Open-label | MGL-3196, Clopidogrel |
| NCT02749578 Drug Interaction Study of MGL-3196 With Atorvastatin | Healthy | P1 | Completed | 14 | Open-label | Atorvastatin, MGL-3196 |